← Open Payments lookup

NPI 1275567695: Open Payments

NPI 1275567695. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,042 in 17 payments from 7 companies in 2025. Trend: 2023 $1,142 · 2024 $1,224 · 2025 $1,042

Food & beverage: $1,042
CompanyPaymentsAmount
AstraZeneca Pharmaceuticals LP7$341
Xeris Pharmaceuticals, Inc.3$262
Optinose US, Inc.1$124
Novo Nordisk Inc1$117
Teva Pharmaceuticals USA, Inc.1$116
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)2$42
Amgen Inc.2$39

Products named: FARXIGA, BREZTRI, GVOKE HYPOPEN, RECORLEV, Xhance, Ozempic, AUSTEDO XR, CAPLYTA.